Aprogen, Inc
Financials
Valuation Metrics
Aprogen, Inc's Market Cap is ₩473B. At end of 2025 it was ₩179B. Ranked #1754 of 2,405 in KR market (top 73%), #690 of 778 on KOSPI (top 89%), #286 of 361 in Capital Goods (top 79%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 47.35B KRW | KR#1,754/2,405 Sec#286/361 |
| Revenue | 138.90B KRW | KR#1,233/2,405 Sec#205/361 |
| Net Income | -138.64B KRW | KR—/2,405 Sec—/361 |
| Total Assets | 674.45B KRW | KR#627/2,405 Sec#116/361 |
| Net Assets | 414.25B KRW | KR#584/2,405 Sec#105/361 |
| Employees | 296 | KR#800/2,405 Sec#142/361 |
| Value | ||
| P/B | 0.11x | KR#29/2,405 Sec#7/361 |
| P/S | 0.34x | KR#715/2,405 Sec#104/361 |
| FCF Yield | -83.01% | KR—/2,405 Sec—/361 |
| Profitability | ||
| ROE | -33.47% | KR#2,198/2,405 Sec#330/361 |
| ROA | -20.56% | KR#2,235/2,405 Sec#342/361 |
| Op. Margin | -66.42% | KR#2,249/2,405 Sec#339/361 |
| Revenue Growth | 9.08% | KR#944/2,405 Sec#147/361 |
| Financial Health | ||
| Debt Ratio | 62.81% | KR#1,125/2,405 Sec#135/361 |
| Total Debt | 179.80B KRW | KR#544/2,405 Sec#97/361 |
| FCF | -39.30B KRW | KR#2,023/2,405 Sec#299/361 |
| Cash | 37.89B KRW | KR#881/2,405 Sec#155/361 |
| Current Ratio | 0.83x | KR#1,899/2,405 Sec#306/361 |
| Dividend | ||
| Div. Yield | 0.00% | KR#1,391/2,405 Sec#227/361 |
| Performance | ||
| 1Y Return | 218.28% | KR#28/2,405 Sec#5/361 |
| 1M Return | -13.74% | KR#1,475/2,405 Sec#172/361 |
| From 52W High | -76.33% | KR#2,218/2,405 Sec#339/361 |
| 1Y MDD | -72.94% | KR#2,078/2,405 Sec#312/361 |
| Trading | ||
| Volume | 84,398 shares | KR#705/2,405 Sec#140/361 |
| Trading Value | 154.5M KRW | KR#1,244/2,405 Sec#225/361 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/361 |
| Per Share | ||
| EPS | -5,405 KRW | KR—/2,405 Sec—/361 |
| BPS | 16,150 KRW | KR#650/2,405 Sec#112/361 |
Company Info
Aprogen, established in 1971 and listed in 1995, completed a merger with a biopharmaceutical development company in 2022. Its subsidiary, Aprogen Biologics, formed a biopharmaceutical division in 2022, while N2TEC specializes in semiconductor component manufacturing and sales. Another subsidiary, APTEN, is engaged in geothermal heating/cooling, fuel cells, lithium, brain disease treatment, and virtual asset businesses. The company maintains a diversified business portfolio including hardfacing, steel, pharmaceuticals, insulation, bio, semiconductors, and renewable energy. Aprogen is headquartered in Seongnam-si, Gyeonggi-do.